Compare Aptiv PLC (APTV) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Viatris Inc — how do they compare? Aptiv PLC trades at $49.62 (market cap $10.30B), while Viatris Inc trades at $16.2 (market cap $18.69B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.95% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | VTRS | |
|---|---|---|
Market Cap | $10.30B | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $17.86 |
52-Week Low | $46.30 | $9.49 |
Enterprise Value | $15.23B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $49.81, up 0.52% on the day, but remains under pressure following a lowered 2026 outlook despite recent earnings beats. Technical indicators are bearish, with the stock near support at $49. Fundamentally, revenue grew to $20.40B in 2025, but net income margin compressed to 1.07%, reflecting margin pressure. The company faces headwinds from China demand weakness and program delays, as highlighted in recent news.
The investment case balances a low valuation (P/E 22.45, P/S 0.52) and strong analyst buy ratings (63.64% buy) against near-term execution risks and cash flow volatility. Upside to the $70.09 consensus target exists if operational improvements materialize, but investors must weigh guidance cuts and competitive threats in the auto sector.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
